Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors
May 15 2019 - 6:39PM
Business Wire
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, today announced
the appointment of Carol Schafer to its Board of Directors. Ms.
Schafer is an industry leader with more than 25 years of investment
banking and equity capital markets experience in the biotechnology
sector.
“We welcome Carol to our board and look forward to her
contributions as we continue to build Five Prime by advancing our
differentiated clinical pipeline, leveraging our discovery
platform, and collaborating with our strategic alliance partners,”
said Aron Knickerbocker, Chief Executive Officer of Five Prime
Therapeutics. “Carol has a long-standing track record as a trusted
strategic and financial advisor to the leadership teams of many
biotech companies, and we are delighted to have her join our
board.”
"I am impressed by the breadth of the pipeline, the management
team and the progress Five Prime has made in executing on its
clinical trials,” said Ms. Schafer. “I am delighted to be joining
this dedicated and experienced team at such an exciting juncture in
the life of the company.”
In addition to serving as a board member and the audit committee
chair at Idera Pharmaceuticals, Ms. Schafer has built a diverse and
successful career spanning executive leadership, finance and
operations. In 2018, she retired from Wells Fargo Securities as
Vice Chair of Equity Capital Markets where she helped to enhance
the firm’s presence and brand in healthcare equity financing by
overseeing 220 transactions that raised nearly $90 billion in
proceeds. Prior to Wells Fargo Securities, Ms. Schafer was Vice
President of Finance and Business Development at Lexicon
Pharmaceuticals. Before joining Lexicon, Ms. Schafer was a Managing
Director in Equity Capital Markets at JPMorgan where she was
responsible for the origination and execution of primary and
secondary equity offerings and other financings for healthcare,
consumer and retail clients. Ms. Schafer received her B.A. from
Boston College and her M.B.A. from the Stern Graduate School of
Business of New York University.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops
innovative protein therapeutics to improve the lives of patients
with serious diseases. Five Prime’s product candidates have
innovative mechanisms of action and address patient populations in
need of better therapies. The company focuses on researching and
developing immuno-oncology and targeted cancer therapies paired
with companion diagnostics to identify patients who are most likely
to benefit from treatment with Five Prime’s product candidates.
Five Prime has entered into strategic collaborations with leading
global pharmaceutical companies and has promising product
candidates in clinical and preclinical development. For more
information, please visit www.fiveprime.com or follow us
on LinkedIn, Twitter and Facebook.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Five Prime's
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties. Actual results may differ materially from these
forward-looking statements. Other factors that may cause actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Five Prime’s filings with the U.S. Securities and Exchange
Commission, including the “Risk Factors” contained therein. Except
as required by law, Five Prime assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190515006044/en/
Media and Investor ContactMartin ForrestVP, Investor
Relations & Corporate CommunicationsFive Prime Therapeutics,
Inc.415-365-5625martin.forrest@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Jul 2023 to Jul 2024